In conclusion, the findings of the present study indicate that among three types of KRAS mutations, G12D/V mutations were consistently associated with less TIL infiltration and shorter RFS in two independent cohorts of stage III CRC patients treated with adjuvant FOLFOX. Here, KRAS is linked to colorectal carcinoma.